Published on : Jul 03, 2017
Nationwide Health Insurance Company Limited, a prominent private health insurance company based in Ghana, has on July 3, 2017 has launched its first ever microinsurance health product-My Health. The comprehensive microinsurance product was developed by Roche Holding AG. The product is expected to provide all residents of the nation access to affordable and quality healthcare and covers essential care.
As stated by Isaac Nartey, Business Development Manager at the company, the offering would cover both the formal and informal sectors, with a special emphasis on the latter. The company will offer plans in the family and individual category to organizations of all sizes, covering a wide spectrum of populations such as traders, union associations, and numerous educational and religious institutions.
Myriad Benefits Make Microinsurance Health Offering Attractive
According to Nationwide Health Insurance Company, its new offering will offer several benefits, such as prescribed drugs, surgical treatments, maternity care, chronic care medical consultation, and diagnostics investigation. The reimbursement also tends to cover hospital admission and accommodation at various partner health facilities.
My Health is anticipated to take private insurance to the next level for the residents in Ghana, opines the provider, with its flexible payment system and an affordable and comprehensive care system. The payment system will offer the member organizations the flexibility to choose the mode of payment of their type—whether daily, monthly, half-yearly, or yearly-with the help of accredited agents or accredited financial institutions or otherwise.
Provision to Include Informal Sector in Ghana Welcome Step
Mr Harold Awuah-Darko, Executive Chairman at the company, considered the microinsurance product an option for mass-market.
Philip Anderson, Country Medical Director at the partnering company Roche, lauded the initiatives of the company to bring into its ambit the informal sector. In addition, he commended its efforts in providing a convenient reimbursement mechanism to facilitate a comprehensive care of breast cancer. This is likely to benefit a large section of women in the informal sector who can ill-afford to pay for the biopsies and treatments related to breast cancer, contends clinicians.